第二リン酸ナトリウム·12水和物

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H319：強い眼刺激

• 注意書き

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

第二リン酸ナトリウム·12水和物 価格

MSDS Information

• Disodium phosphate dodecahydrate

第二リン酸ナトリウム·12水和物 化学特性,用途語,生産方法

• 外観

  無色又は白色の結晶

• 定義

  本品は、リン酸(*)の二ナトリウム塩であり、次の化学式で表される。
  参照表示名称：リン酸

• 溶解性

  水に溶けやすく、エタノールにほとんど溶けない。

• 用途

  大気中のオキシダント測定用吸収液調製用。

• 用途

  汎用試薬、調製液原料。

• 用途

  食品添加物。

• 用途

  医薬品、製剤原料。

• 用途

  汎用試薬、調製液原料、りん酸塩pH緩衝液原料。

• 化粧品の成分用途

  pH調整剤、腐蝕防止剤、緩衝剤、香料

• 効能

  下剤

• 使用上の注意

  温乾燥空気中で風解する。

• 化学的特性

  white crystals

• 使用

  Sodium Phosphate Dibasic Dodecahydrate is used in method for preparing self-supporting membrane.

• 調製方法

  Either bone phosphate (bone ash), obtained by heating bones to whiteness, or the mineral phosphorite is used as a source of tribasic calcium phosphate, which is the starting material in the industrial production of dibasic sodium phosphate.
  Tribasic calcium phosphate is finely ground and digested with sulfuric acid. This mixture is then leached with hot water and neutralized with sodium carbonate, and dibasic sodium phosphate is crystallized from the filtrate.

• 定義

  ChEBI: A hydrate that is the dodecahydrate form of disodium hydrogenphosphate

• 一般的な説明

  Sodium phosphate is a colorless crystalline sodium salt. It is widely used as a buffer in molecular biology, biochemistry, and chromatographic studies. It exists in three forms: monobasic (NaH₂PO₄), dibasic (Na₂HPO₄), and tribasic (Na₃PO₄). Monobasic and dibasic forms in varying ratios are commonly used to compose the neutral sodium phosphate buffer solution.

• 応用例（製薬）

  Dibasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a buffering agent and as a sequestering agent. Therapeutically, dibasic sodium phosphate is used as a mild laxative and in the treatment of hypophosphatemia.
  Dibasic sodium phosphate is also used in food products; for example as an emulsifier in processed cheese.

• 安全性

  Dibasic sodium phosphate is widely used as an excipient in parenteral, oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the body and is involved in many physiological processes since it is the principal anion of intracellular fluid. Most foods contain adequate amounts of phosphate, making hypophosphatemia (phosphate deficiency) virtually unknown except for certain disease states or in patients receiving total parenteral nutrition. Treatment is usually by the oral administration of up to 100 mmol of phosphate daily.
  Approximately two-thirds of ingested phosphate is absorbed from the gastrointestinal tract, virtually all of it being excreted in the urine, and the remainder is excreted in the feces.
  Excessive administration of phosphate, particularly intravenously, rectally, or in patients with renal failure, can cause hyperphosphatemia that may lead to hypocalcemia or other severe electrolyte imbalances. Adverse effects occur less frequently following oral consumption, although phosphates act as mild saline laxatives when administered orally or rectally. Consequently, gastrointestinal disturbances including diarrhea, nausea, and vomiting may occur following the use of dibasic sodium phosphate as an excipient in oral formulations. However, the level of dibasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse effects.
  LD50 (rat, oral): 17 g/kg

• 貯蔵

  The anhydrous form of dibasic sodium phosphate is hygroscopic. When heated to 40℃, the dodecahydrate fuses; at 100℃ it loses its water of crystallization; and at a dull-red heat (about 240℃) it is converted into the pyrophosphate, Na4P2O7. Aqueous solutions of dibasic sodium phosphate are stable and may be sterilized by autoclaving.
  The bulk material should be stored in an airtight container, in a cool, dry place.

• 不和合性

  Dibasic sodium phosphate is incompatible with alkaloids, antipyrine, chloral hydrate, lead acetate, pyrogallol, resorcinol and calcium gluconate, and ciprofloxacin. Interaction between calcium and phosphate, leading to the formation of insoluble calcium-phosphate precipitates, is possible in parenteral admixtures.

• 規制状況(Regulatory Status)

  GRAS listed. Accepted in Europe for use as a food additive. Included in the FDA Inactive Ingredients Database (injections; infusions; nasal, ophthalmic, oral, otic, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

第二リン酸ナトリウム·12水和物 上流と下流の製品情報

第二リン酸ナトリウム·12水和物 生産企業

Global(461)Suppliers

第二リン酸ナトリウム·12水和物 スペクトルデータ(IR1、IR2)

10039-32-4, 第二リン酸ナトリウム·12水和物 キーワード